Erratum: Prevalence and progression rate of diabetic retinopathy in type 2 diabetes patients in correlation with the duration of diabetes (Experimental and Clinical Endocrinology and Diabetes (2018) 126 (570-576) DOI: 10.1055/s-0043-120570);Prevalence and Progression Rate of Diabetic Retinopathy in Type 2 Diabetes Patients in Correlation with the Duration of Diabetes

Experimental and Clinical Endocrinology and Diabetes

Volumn 126, Issue 9, 2018, Pages 570-576

  Voigt, Margarete ^a   Schmidt, Sebastian ^a   Lehmann, Thomas ^a   Köhler, Benjamin ^a   Kloos, Christoph ^a   Voigt, Ulricha ^a   Meller, Daniel ^a   Wolf, Gunther ^a   Müller, Ulrich A ^a   Müller, Nicolle ^a  

^a JENA UNIVERSITY HOSPITAL   (Germany)

Author keywords

Diabetes duration; Diabetes mellitus type 2; Diabetic retinopathy; Prevalence; Screening interval

Indexed keywords

ADULT; ARTICLE; COHORT ANALYSIS; DETERIORATION; DIABETIC RETINOPATHY; DISEASE ASSOCIATION; DISEASE DURATION; EYE PHOTOGRAPHY; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON INSULIN DEPENDENT DIABETES MELLITUS; PREVALENCE; PRIORITY JOURNAL; RETROSPECTIVE STUDY; AGED; COMPLICATION; DIAGNOSTIC IMAGING; DISEASE EXACERBATION; RETINOSCOPY; STATISTICS AND NUMERICAL DATA; TIME FACTOR;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC RETINOPATHY; DISEASE PROGRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; PREVALENCE; RETINOSCOPY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 85035768515     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/a-0757-3796     Document Type: Erratum

References (33)

1. Kollias A. N. Ulbig M. W. Diabetic retinopathy: Early diagnosis and effective treatment. Deutsches Arzteblatt International: 2010; 107 75
2. Zhang X. Saaddine J. B. Chou C. F. et al. Prevalence of diabetic retinopathy in the United States, 2005-2008. Jama: 2010; 304 649 656
3. Cheung N. Mitchell P. Wong T. Y. Diabetic retinopathy. Lancet: 2010; 376 124 136
4. Unwin N. Gan D. Whiting D. The IDF Diabetes Atlas: Providing evidence, raising awareness and promoting action. Diabetes research and clinical practice: 2010; 87 2 3
5. Jonsson B. Board C-A. Revealing the cost of Type II diabetes in Europe. Diabetologia: 2002; 45 S5 S12
6. Raum P. Lamparter J. Ponto K. A. et al. Prevalence and cardiovascular associations of diabetic retinopathy and maculopathy: Results from the gutenberg health study. PloS one: 2015; 10 e0127188
7. Group ETDRSR Grading diabetic retinopathy from stereoscopic color fundus photographs--an extension of the modified Airlie House classification: ETDRS report number 10. Ophthalmology: 1991; 98 786 806
8. Wilkinson C. P. Ferris F. L. 3rd. Klein R. E. et al. Proposed international clinical diabetic retinopathy and diabetic macular edema disease severity scales. Ophthalmology: 2003; 110 1677 1682
9. Nentwich M. Lemmen K. Ulbig M. Stadieneinteilung und Therapie der diabetischen Retinopathie und Makulopathie. Z prakt Augenheilk: 2010; 31 491 499
10. Looker H. C. Nyangoma S. O. Cromie D. T. et al. Predicted impact of extending the screening interval for diabetic retinopathy: The Scottish Diabetic Retinopathy Screening programme. Diabetologia: 2013; 56 1716 1725
11. Zavrelova H. Hoekstra T. Alssema M. et al. Progression and regression: distinct developmental patterns of diabetic retinopathy in patients with type 2 diabetes treated in the diabetes care system west-friesland, the Netherlands. Diabetes care: 2011; 34 867 872
12. Hesse L. Grüsser M. Hoffstadt K. et al. Populationsbezogene Erhebung zur diabetischen Retinopathie in Wolfsburg. Der Ophthalmologe: 2001; 98 1065 1068
13. Blum PD M. Kloos C. Müller N. et al. Prävalenz der diabetischen Retinopathie. Der Ophthalmologe: 2007; 104 499 504
14. Muller N. Heller T. Freitag M. H. et al. Healthcare utilization of people with type 2 diabetes in Germany: An analysis based on health insurance data. Diabetic medicine: a journal of the British Diabetic Association: 2015; 32 951 957
15. Hagen B. Altenhofen L. Groos S. et al. Nordrheinische Gemeinsame Einrichtung Disease-Management-Programme (ed.): Qualitätssicherungsbericht 2012 Disease-Management-Programme in Nordrhein. Düsseldorf Nordrheinische Gemeinsame Einrichtung: 2013
16. Hammes H. P. Welp R. Kempe H. P. et al. Risk Factors for Retinopathy and DME in Type 2 Diabetes-Results from the German/Austrian DPV Database. PloS one: 2015; 10 e0132492
17. Kloos C. Muller N. Wolf G. et al. Better HbA1c and blood pressure control in patients with diabetes mellitus treated at a primary health care level 10 years after initiation of a diabetes quality improvement program. Experimental and clinical endocrinology & diabetes: official journal, German Society of Endocrinology [and] German Diabetes Association: 2011; 119 459 462
18. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus The diabetes control and complications trial research group. The New England Journal of Medicine: 1993; 329 977 986
19. Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) UK Prospective Diabetes Study (UKPDS) Group. Lancet: 1998; 352 837 853
20. Klein R. Klein B. E. Are individuals with diabetes seeing better?: a long-term epidemiological perspective. Diabetes: 2010; 59 1853 1860
21. Bachmann M. O. Nelson S. J. Impact of diabetic retinopathy screening on a British district population: case detection and blindness prevention in an evidence-based model. Journal of Epidemiology and Community Health: 1998; 52 45 52
22. Mehlsen J. Erlandsen M. Poulsen P. L. et al. Individualized optimization of the screening interval for diabetic retinopathy: A new model. Acta ophthalmologica: 2012; 90 109 114
23. Aspelund T. Thornorisdottir O. Olafsdottir E. et al. Individual risk assessment and information technology to optimise screening frequency for diabetic retinopathy. Diabetologia: 2011; 54 2525 2532
24. Agardh E. Tababat-Khani P. Adopting 3-year screening intervals for sight-threatening retinal vascular lesions in type 2 diabetic subjects without retinopathy. Diabetes care: 2011; 34 1318 1319
25. Younis N. Broadbent D. M. Vora J. P. Liverpool Diabetic Eye S et al. Incidence of sight-threatening retinopathy in patients with type 2 diabetes in the Liverpool Diabetic Eye Study: A cohort study. Lancet: 2003; 361 195 200
26. Jones C. D. Greenwood R. H. Misra A. et al. Incidence and progression of diabetic retinopathy during 17 years of a population-based screening program in England. Diabetes care: 2012; 35 592 596
27. Porta M. Maurino M. Severini S. et al. Clinical characteristics influence screening intervals for diabetic retinopathy. Diabetologia: 2013; 56 2147 2152
28. Thomas R. L. Dunstan F. Luzio S. D. et al. Incidence of diabetic retinopathy in people with type 2 diabetes mellitus attending the Diabetic Retinopathy Screening Service for Wales: retrospective analysis. Bmj: 2012; 344 e874
29. Olafsdottir E. Stefansson E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. The British journal of ophthalmology: 2007; 91 1599 1601
30. Vijan S. Hofer T. P. Hayward R. A. Cost-utility analysis of screening intervals for diabetic retinopathy in patients with type 2 diabetes mellitus. Jama: 2000; 283 889 896
31. Yau J. W. Rogers S. L. Kawasaki R. et al. Global prevalence and major risk factors of diabetic retinopathy. Diabetes care: 2012; 35 556 564
32. Hemmingsen B. Lund S. S. Gluud C. et al. Targeting intensive glycaemic control versus targeting conventional glycaemic control for type 2 diabetes mellitus. The Cochrane database of systematic reviews: 2013; 11 CD008143
33. Fullerton D. A. Sundt T. M. Process versus outcome: the sugar window. The Annals of thoracic surgery: 2014; 98 1902 1904